CD274 and ovarian carcinoma: Furthermore, the L-MOCA trial analysis identified HRD as an effective biomarker for platinum-sensitive recurrent ovarian cancer, while high PD-L1 expression in BRCAmutated patients appeared to reduce Olaparib efficacy (75).